 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | fidasimtamab (IBI315) / Hanmi, Innovent Biologics
Journal, PD(L)-1 Biomarker, IO biomarker: Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis. (Pubmed Central) - Aug 17, 2023
Notably, GSDMB is found to be elevated in Her2-positive gastric cancer cells, providing a rationale for IBI315's efficacy. IBI315 is supported here as a promising bispecific antibody-based immunotherapy approach for Her2-positive gastric cancer in preclinical studies, broadening the therapeutic landscape of this patient population.
- | New P1/2 trial, IO biomarker, Metastases: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes (clinicaltrials.gov) - Nov 8, 2022
P1/2, N=45, Not yet recruiting, Sponsor: Henan Cancer Hospital
- ||| fidasimtamab (IBI315) / Hanmi, Innovent Biologics
Enrollment open, Metastases: A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor (clinicaltrials.gov) - Dec 1, 2019
P1a/1b, N=191, Recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
IBI315 is supported here as a promising bispecific antibody-based immunotherapy approach for Her2-positive gastric cancer in preclinical studies, broadening the therapeutic landscape of this patient population. Not yet recruiting --> Recruiting
- ||| fidasimtamab (IBI315) / Hanmi, Innovent Biologics
New P1 trial, Metastases: A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor (clinicaltrials.gov) - Nov 14, 2019
P1a/1b, N=191, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.